259 related articles for article (PubMed ID: 31284853)
21. Targets and Patented Drugs for Chemotherapy of Chagas Disease in the Last 15 Years-Period.
Duschak VG
Recent Pat Antiinfect Drug Discov; 2016; 11(2):74-173. PubMed ID: 27784230
[TBL] [Abstract][Full Text] [Related]
22. Proteomic and bioinformatic analysis of Trypanosoma cruzi chemotherapy and potential drug targets: new pieces for an old puzzle.
Sadok Menna-Barreto RF; Belloze KT; Perales J; Silva FP
Curr Drug Targets; 2014 Mar; 15(3):255-71. PubMed ID: 24041335
[TBL] [Abstract][Full Text] [Related]
23. Computational Drug Repositioning by Target Hopping: A Use Case in Chagas Disease.
Haupt VJ; Aguilar Uvalle JE; Salentin S; Daminelli S; Leonhardt F; Konc J; Schroeder M
Curr Pharm Des; 2016; 22(21):3124-34. PubMed ID: 26873186
[TBL] [Abstract][Full Text] [Related]
24. Molecular modeling and structure-activity relationships for a series of benzimidazole derivatives as cruzain inhibitors.
Pauli I; Ferreira LG; de Souza ML; Oliva G; Ferreira RS; Dessoy MA; Slafer BW; Dias LC; Andricopulo AD
Future Med Chem; 2017 May; 9(7):641-657. PubMed ID: 28509592
[TBL] [Abstract][Full Text] [Related]
25. Rate-of-Kill (RoK) assays to triage large compound sets for Chagas disease drug discovery: Application to GSK Chagas Box.
Cantizani J; Gamallo P; Cotillo I; Alvarez-Velilla R; Martin J
PLoS Negl Trop Dis; 2021 Jul; 15(7):e0009602. PubMed ID: 34270544
[TBL] [Abstract][Full Text] [Related]
26. Challenges in Chagas Disease Drug Discovery: A Review.
Paucar R; Moreno-Viguri E; Pérez-Silanes S
Curr Med Chem; 2016; 23(28):3154-3170. PubMed ID: 27356544
[TBL] [Abstract][Full Text] [Related]
27. Discovery of Potent, Reversible, and Competitive Cruzain Inhibitors with Trypanocidal Activity: A Structure-Based Drug Design Approach.
de Souza ML; de Oliveira Rezende Junior C; Ferreira RS; Espinoza Chávez RM; Ferreira LLG; Slafer BW; Magalhães LG; Krogh R; Oliva G; Cruz FC; Dias LC; Andricopulo AD
J Chem Inf Model; 2020 Feb; 60(2):1028-1041. PubMed ID: 31765144
[TBL] [Abstract][Full Text] [Related]
28. Identification of Inhibitors to
Matutino Bastos T; Botelho Pereira Soares M; Haddad Franco C; Alcântara L; Antonini L; Sabatino M; Mautone N; Holanda Freitas-Junior L; Moraes CB; Ragno R; Rotili D; Schenkman S; Mai A; Silvio Moretti N
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32455951
[TBL] [Abstract][Full Text] [Related]
29. Reversible cysteine protease inhibitors show promise for a Chagas disease cure.
Ndao M; Beaulieu C; Black WC; Isabel E; Vasquez-Camargo F; Nath-Chowdhury M; Massé F; Mellon C; Methot N; Nicoll-Griffith DA
Antimicrob Agents Chemother; 2014; 58(2):1167-78. PubMed ID: 24323474
[TBL] [Abstract][Full Text] [Related]
30. New Approaches for the Treatment of Chagas Disease.
Pandey RP; Nascimento MS; Moore CE; Raj VS; Kalil J; Cunha-Neto E
Curr Drug Targets; 2021; 22(7):835-841. PubMed ID: 33238855
[TBL] [Abstract][Full Text] [Related]
31. Development of alpha-keto-based inhibitors of cruzain, a cysteine protease implicated in Chagas disease.
Choe Y; Brinen LS; Price MS; Engel JC; Lange M; Grisostomi C; Weston SG; Pallai PV; Cheng H; Hardy LW; Hartsough DS; McMakin M; Tilton RF; Baldino CM; Craik CS
Bioorg Med Chem; 2005 Mar; 13(6):2141-56. PubMed ID: 15727867
[TBL] [Abstract][Full Text] [Related]
32. In Silico Drug Repositioning for Chagas Disease.
Bellera CL; Alberca LN; Sbaraglini ML; Talevi A
Curr Med Chem; 2020; 27(5):662-675. PubMed ID: 31622200
[TBL] [Abstract][Full Text] [Related]
33. Repositioned Drugs for Chagas Disease Unveiled via Structure-Based Drug Repositioning.
Adasme MF; Bolz SN; Adelmann L; Salentin S; Haupt VJ; Moreno-Rodríguez A; Nogueda-Torres B; Castillo-Campos V; Yepez-Mulia L; De Fuentes-Vicente JA; Rivera G; Schroeder M
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233837
[TBL] [Abstract][Full Text] [Related]
34. Chagas Disease Chemotherapy: What Do We Know So Far?
Zuma AA; de Souza W
Curr Pharm Des; 2021; 27(38):3963-3995. PubMed ID: 33593251
[TBL] [Abstract][Full Text] [Related]
35. Altered expression of cruzipain and a cathepsin B-like target in a Trypanosoma cruzi cell line displaying resistance to synthetic inhibitors of cysteine-proteinases.
Yong V; Schmitz V; Vannier-Santos MA; de Lima AP; Lalmanach G; Juliano L; Gauthier F; Scharfstein J
Mol Biochem Parasitol; 2000 Jun; 109(1):47-59. PubMed ID: 10924756
[TBL] [Abstract][Full Text] [Related]
36. Structural design, synthesis and pharmacological evaluation of 4-thiazolidinones against Trypanosoma cruzi.
de Oliveira Filho GB; de Oliveira Cardoso MV; Espíndola JW; Ferreira LF; de Simone CA; Ferreira RS; Coelho PL; Meira CS; Magalhaes Moreira DR; Soares MB; Lima Leite AC
Bioorg Med Chem; 2015 Dec; 23(23):7478-86. PubMed ID: 26549870
[TBL] [Abstract][Full Text] [Related]
37. Biological factors that impinge on Chagas disease drug development.
Francisco AF; Jayawardhana S; Lewis MD; Taylor MC; Kelly JM
Parasitology; 2017 Dec; 144(14):1871-1880. PubMed ID: 28831944
[TBL] [Abstract][Full Text] [Related]
38. Investigating the structure-activity relationships of N'-[(5-nitrofuran-2-yl) methylene] substituted hydrazides against Trypanosoma cruzi to design novel active compounds.
Palace-Berl F; Pasqualoto KFM; Zingales B; Moraes CB; Bury M; Franco CH; da Silva Neto AL; Murayama JS; Nunes SL; Silva MN; Tavares LC
Eur J Med Chem; 2018 Jan; 144():29-40. PubMed ID: 29247858
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of novel benznidazole solutions during the experimental infection with Trypanosoma cruzi.
Manarin R; Lamas MC; Bottasso E; Serra E; Revelli S; Salomón CJ
Parasitol Int; 2013 Feb; 62(1):79-81. PubMed ID: 22975280
[TBL] [Abstract][Full Text] [Related]
40. An insight on targets and patented drugs for chemotherapy of Chagas disease.
Duschak VG; Couto AS
Recent Pat Antiinfect Drug Discov; 2007 Jan; 2(1):19-51. PubMed ID: 18221162
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
